Status:
COMPLETED
DIMS-myopia Progression ADN Axial Length Growth
Lead Sponsor:
Tianjin Eye Hospital
Conditions:
Myopia, Progressive
Eligibility:
All Genders
6-13 years
Phase:
NA
Brief Summary
To confirm the efficacy of DIMS lenses in controlling myopia progression, we planned a prospective randomized controlled clinical study.
Detailed Description
The subjects were randomly assigned into two groups: the control group (SV) and the experimental group (DIMS). The clinical trial assistant took the glasses before examination and returned them after ...
Eligibility Criteria
Inclusion
- The subjects had spherical RE of -1.00 to -6.50 D, astigmatism ≤ 4.00 D, anisometropia ≤ 1.50 D
- Best corrected visual acuity (BCVA) equal to or better than logMAR 0.0 (20/20) in both eyes.
Exclusion
- Candidate subjects were excluded from the study if they had strabismus, ocular limitations, or systemic abnormalities affecting vision and ocular motility.
Key Trial Info
Start Date :
June 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2021
Estimated Enrollment :
82 Patients enrolled
Trial Details
Trial ID
NCT05300321
Start Date
June 1 2019
End Date
April 1 2021
Last Update
April 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tianjin Eye Hospital
Tianjin, China